Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ultrasound could spot deadly lung disease in scleroderma patients early

NCT ID NCT04725786

Diagnosis Sponsor: University Hospital, Tours Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a painless, non-radiation ultrasound of the chest can find early signs of lung scarring in people with scleroderma. Thirty patients without known lung disease on CT scans underwent thoracic ultrasound. The goal was to see how often ultrasound detects hidden lung problems, potentially offering a cheaper and easier screening tool than current methods.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
thoracic ultrasound
What this could lead to
If successful, this could provide a non-invasive, low-cost way to catch lung disease early in scleroderma patients, improving treatment timing.
What could go wrong
This is a small pilot study with only 30 participants, so results may not apply broadly. Ultrasound might miss some cases or be less accurate than standard CT scans.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

30 people

The number who actually took part.

Started

Mar 2021

Finished

Jun 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years old * Diagnosis of systemic scleroderma according to EULAR/ACR 2013 criteria * Absence of diffuse interstitial lung disease proven by scanner on the day of inclusion * Forced vital capacity ≥ 80% of the value predicted on the last respiratory function test performed. * Carbon monoxide diffusion capacity corrected for hemoglobinemia ≥ 70% of the value predicted on the last respiratory function test performed. * Patient capable of performing functional exploration during the year * Affiliation to a social security system * Patient who has given free and informed consent Exclusion Criteria: * Any other connectivity associated to systemic sleroderma * Any chronic pathologies, co-morbidities, history judged by the investigator as being likely to lead to complications for the patient and/or which may impact the results of functional exploration during exercise. * All known fibrotic and/or obstructive respiratory pathologies. * Presence of echocardiographic signs of pulmonary arterial hypertension according to 2015 criteria * Diagnosis of left heart disease * Cumulative smoking \> 10 packs.years * Infectious pneumonia within 90 days prior to inclusion * Acute respiratory illness requiring hospitalization within one year prior to inclusion * Pregnant or breastfeeding woman * Refusal to participate in the study * Refusal to use the data * Adults under legal protection (temporary protection measure, curatorship, guardianship)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Systemic sclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Systemic sclerosis

Contacts and locations

Locations

  • CHRU Tours

    Tours, 37044, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.